Literature DB >> 27069766

(68)Ga-DOTATOC PET and gene expression profile in patients with neuroendocrine carcinomas: strong correlation between PET tracer uptake and gene expression of somatostatin receptor subtype 2.

Ingrid H Olsen1, Seppo W Langer2, Birgitte H Federspiel3, Jytte Oxbøl4, Annika Loft4, Anne Kiil Berthelsen4, Jann Mortensen4, Peter Oturai4, Ulrich Knigge5, Andreas Kjær4.   

Abstract

Somatostatin receptor expression on both protein and gene expression level was compared with in vivo (68)Ga-DOTATOC PET/CT in patients with neuroendocrine carcinomas (NEC). Twenty-one patients with verified NEC who underwent a (68)Ga-DOTATOC PET/CT between November 2012 and May 2014, were retrospectively included. By real-time polymerase chain reaction, we quantitatively determined the gene expression of several genes and compared with (68)Ga-DOTATOC PET uptake. By immunohistochemistry we qualitatively studied the expression of assorted proteins in NEC. The median age at diagnosis was 68 years (range 41-84) years. All patients had WHO performance status 0-1. Median Ki67 index was 50% (range 20-100%). Gene expression of somatostatin receptor subtype (SSTR) 2 and Ki67 were both positively correlated to the (68)Ga-DOTATOC uptake (r=0.89; p<0.0001 and r=0.5; p=0.021, respectively). Furthermore, SSTR2 and SSTR5 gene expression were strongly and positively correlated (r=0.57; p=0.006). This study as the first verifies a positive and close correlation of (68)Ga-DOTATOC uptake and gene expression of SSTR2 in NEC. SSTR2 gene expression has a stronger correlation to (68)Ga-DOTATOC uptake than SSTR5. In addition, the results indicate that the gene expression levels of SSTR2 and SSTR5 at large follow one another.

Entities:  

Keywords:  68Ga-DOTATOC PET/CT; Neuroendocrine carcinoma; gene expression; imaging; immunohistochemistry; mammalian target of rapamycin; neuroendocrine tumors; somatostatin receptor type 2; somatostatin receptor type 5; urokinase-type plasminogen activator receptor

Year:  2016        PMID: 27069766      PMCID: PMC4749505     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  54 in total

1.  Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis.

Authors:  M Papotti; M Bongiovanni; M Volante; E Allìa; S Landolfi; L Helboe; M Schindler; S L Cole; G Bussolati
Journal:  Virchows Arch       Date:  2002-03-23       Impact factor: 4.064

2.  Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.

Authors:  Irene Virgolini; Valentina Ambrosini; Jamshed B Bomanji; Richard P Baum; Stefano Fanti; Michael Gabriel; Nikolaos D Papathanasiou; Giovanna Pepe; Wim Oyen; Clemens De Cristoforo; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-10       Impact factor: 9.236

3.  Characterization of neuroendocrine tumors of the pancreas by real-time quantitative polymerase chain reaction. A methodological approach.

Authors:  Laura Annaratone; Marco Volante; Sofia Asioli; Nelson Rangel; Gianni Bussolati
Journal:  Endocr Pathol       Date:  2013-06       Impact factor: 3.943

4.  VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway.

Authors:  Karine Villaume; Martine Blanc; Géraldine Gouysse; Thomas Walter; Christophe Couderc; Mimoun Nejjari; Cécile Vercherat; Martine Cordier-Bussat; Colette Roche; Jean-Yves Scoazec
Journal:  Neuroendocrinology       Date:  2010-04-13       Impact factor: 4.914

Review 5.  Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.

Authors:  Kjell E Oberg; Jean-Claude Reubi; Dik J Kwekkeboom; Eric P Krenning
Journal:  Gastroenterology       Date:  2010-07-13       Impact factor: 22.682

6.  First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts.

Authors:  Morten Persson; Hongguang Liu; Jacob Madsen; Zhen Cheng; Andreas Kjaer
Journal:  Nucl Med Biol       Date:  2013-04-18       Impact factor: 2.408

7.  Lanreotide in metastatic enteropancreatic neuroendocrine tumors.

Authors:  Martyn E Caplin; Marianne Pavel; Jarosław B Ćwikła; Alexandria T Phan; Markus Raderer; Eva Sedláčková; Guillaume Cadiot; Edward M Wolin; Jaume Capdevila; Lucy Wall; Guido Rindi; Alison Langley; Séverine Martinez; Joëlle Blumberg; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2014-07-17       Impact factor: 91.245

Review 8.  Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours.

Authors:  W W de Herder; L J Hofland; A J van der Lely; S W J Lamberts
Journal:  Endocr Relat Cancer       Date:  2003-12       Impact factor: 5.678

9.  Dosimetry of 64Cu-DOTA-AE105, a PET tracer for uPAR imaging.

Authors:  Morten Persson; Henrik H El Ali; Tina Binderup; Andreas Pfeifer; Jacob Madsen; Palle Rasmussen; Andreas Kjaer
Journal:  Nucl Med Biol       Date:  2013-12-18       Impact factor: 2.408

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  8 in total

Review 1.  Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-02       Impact factor: 3.243

2.  64Cu-DOTATATE PET/CT and Prediction of Overall and Progression-Free Survival in Patients with Neuroendocrine Neoplasms.

Authors:  Esben Andreas Carlsen; Camilla Bardram Johnbeck; Tina Binderup; Mathias Loft; Andreas Pfeifer; Jann Mortensen; Peter Oturai; Annika Loft; Anne Kiil Berthelsen; Seppo W Langer; Ulrich Knigge; Andreas Kjaer
Journal:  J Nucl Med       Date:  2020-02-28       Impact factor: 10.057

Review 3.  [Neuroendocrine tumors of the stomach, duodenum and pancreas : Value of (hybrid) radiological diagnostics].

Authors:  J Rübenthaler; C Auernhammer; I Harun; J Ricke; C C Cyran
Journal:  Radiologe       Date:  2019-11       Impact factor: 0.635

4.  Prospective study of dynamic whole-body 68Ga-DOTATOC-PET/CT acquisition in patients with well-differentiated neuroendocrine tumors.

Authors:  Philippe Thuillier; David Bourhis; Jean Philippe Metges; Romain Le Pennec; Karim Amrane; Ulrike Schick; Frédérique Blanc-Beguin; Simon Hennebicq; Pierre-Yves Salaun; Véronique Kerlan; Nicolas Karakatsanis; Ronan Abgral
Journal:  Sci Rep       Date:  2021-03-01       Impact factor: 4.379

5.  Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin.

Authors:  Rebekka Mai; Daniel Kaemmerer; Tina Träger; Elisa Neubauer; Jörg Sänger; Richard P Baum; Stefan Schulz; Amelie Lupp
Journal:  Sci Rep       Date:  2019-03-13       Impact factor: 4.379

6.  Correlation of Somatostatin Receptor 1-5 Expression, [68Ga]Ga-DOTANOC, [18F]F-FDG PET/CT and Clinical Outcome in a Prospective Cohort of Pancreatic Neuroendocrine Neoplasms.

Authors:  Susanna Majala; Tiina Vesterinen; Hanna Seppänen; Harri Mustonen; Jari Sundström; Camilla Schalin-Jäntti; Risto Gullichsen; Jukka Schildt; Jukka Kemppainen; Johanna Arola; Saila Kauhanen
Journal:  Cancers (Basel)       Date:  2021-12-29       Impact factor: 6.639

Review 7.  PET-CT in Clinical Adult Oncology-VI. Primary Cutaneous Cancer, Sarcomas and Neuroendocrine Tumors.

Authors:  Gabriel C Fine; Matthew F Covington; Bhasker R Koppula; Ahmed Ebada Salem; Richard H Wiggins; John M Hoffman; Kathryn A Morton
Journal:  Cancers (Basel)       Date:  2022-06-08       Impact factor: 6.575

Review 8.  Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy.

Authors:  Alberto Signore; Chiara Lauri; Sveva Auletta; Michela Varani; Livia Onofrio; Andor W J M Glaudemans; Francesco Panzuto; Paolo Marchetti
Journal:  Cancers (Basel)       Date:  2020-03-25       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.